Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
entities : Sorrento therapeutics, inc. source : Www.globenewswire.com save search
Scilex Holding Company Announces that the U.S. Bankruptcy Court has Extended the Lockup Period on Shares of Scilex Stock Previously Distributed by Sorrento to its Stockholders as a Dividend
Published: 2024-03-27 (Crawled : 13:00) - globenewswire.com
SCLX | $0.984 3.43% 3.31% 550K
|
|
| O: -0.66%
H: 10.33%
C: 7.33%
SRNE | $0.015 -8.85% 140K
|
Health Technology
|
| O: -11.11%
H: 12.5%
C: 0.0%
company
Scilex Holding Company’s Wholly Owned Subsidiary, Scilex Pharmaceuticals Inc., Entered into a Definitive Mutual Release and Settlement Agreement with Virpax Pharmaceuticals, Inc. Relating to the Previously Announced Term Sheet with Virpax in Respect of Such Release and Settlement
Published: 2024-03-15 (Crawled : 13:00) - globenewswire.com
SCLX | $0.984 3.43% 3.31% 550K
|
|
| O: 0.72%
H: 2.89%
C: -2.14%
SRNE | $0.015 -8.85% 140K
|
Health Technology
|
| O: -7.14%
H: 46.15%
C: 38.46%
virpax wholly pharmaceuticals agreement
Scilex Holding Company Announces that the Official Committee of Unsecured Creditors of Sorrento Therapeutics, Inc., has Filed a Motion with the U.S. Bankruptcy Court to Extend the Lockup Period on Shares of Scilex Stock Previously Distributed by Sorrento to its Stockholders as a Dividend from March 31, 2024 to September 30, 2024
Published: 2024-03-02 (Crawled : 00:20) - globenewswire.com
SCLX | $0.984 3.43% 3.31% 550K
|
| Email alert
Add to watchlist
SRNE | $0.015 -8.85% 140K
|
Health Technology
| Email alert
Add to watchlist
company
Scilex Holding Company’s Wholly Owned Subsidiary, Scilex Pharmaceuticals Inc., Enters into a Term Sheet with Virpax Pharmaceuticals, Inc. Regarding a Mutual Release and Settlement Agreement
Published: 2024-02-26 (Crawled : 22:00) - globenewswire.com
SCLX | $0.984 3.43% 3.31% 550K
|
|
| O: 1.45%
H: 15.24%
C: 10.0%
SRNE | $0.015 -8.85% 140K
|
Health Technology
|
| O: 7.14%
H: 66.67%
C: -11.0%
virpax wholly pharmaceuticals agreement
Scilex Holding Company Chief Executive Officer and President Issues Letter to Stockholders Highlighting 2023 Accomplishments and Outlook for 2024
Published: 2024-01-08 (Crawled : 14:00) - globenewswire.com
SCLX | $0.984 3.43% 3.31% 550K
|
|
| O: 3.82%
H: 5.76%
C: 1.04%
SRNE | $0.015 -8.85% 140K
|
Health Technology
|
| O: -2.03%
H: 3.42%
C: -1.08%
company
UPDATE -- Scilex Holding Company Files Emergency Motion in the United States Bankruptcy Court for the Southern District of Texas for Entry of an Order Compelling the Production of Books and Records from certain Brokers, Dealers, Banks and other Nominees Pursuant to Rule 2004 of the Federal Rules of Bankruptcy Procedure
Published: 2023-10-27 (Crawled : 20:00) - globenewswire.com
SCLX | $0.984 3.43% 3.31% 550K
|
| Email alert
Add to watchlist
SRNE | $0.015 -8.85% 140K
|
Health Technology
| Email alert
Add to watchlist
company update order
Scilex Holding Company Files Emergency Motion in the United States Bankruptcy Court for the Southern District of Texas for Entry of an Order Compelling the Production of Books and Records from certain Brokers, Dealers, Banks and other Nominees Pursuant to Rule 2004 of the Federal Rules of Bankruptcy Procedure
Published: 2023-10-27 (Crawled : 18:00) - globenewswire.com
SRNE | $0.015 -8.85% 140K
|
Health Technology
| Email alert
Add to watchlist
SCLX | $0.984 3.43% 3.31% 550K
|
| Email alert
Add to watchlist
company order
Scilex Holding Company Retains Warshaw Burstein, LLP and Christian Attar Law to Investigate Potential Naked Short Selling, Short Positions, Stock Lending Program Activities and Market Manipulation of Its Stock Price
Published: 2023-10-07 (Crawled : 00:20) - globenewswire.com
SCLX | $0.984 3.43% 3.31% 550K
|
| Email alert
Add to watchlist
SRNE | $0.015 -8.85% 140K
|
Health Technology
| Email alert
Add to watchlist
company program potential market
Scilex Holding Company Provides Notice to All Lenders of Short Positions in the Restricted Dividend Shares of Scilex Holding Company
Published: 2023-10-04 (Crawled : 17:00) - globenewswire.com
SCLX | $0.984 3.43% 3.31% 550K
|
|
| O: -1.59%
H: 14.52%
C: 13.71%
SRNE | $0.015 -8.85% 140K
|
Health Technology
|
| O: -2.26%
H: 8.8%
C: 1.87%
company
Scilex Holding Company Provides Notice to All Record Holders and Beneficial Owners of Restricted Shares of Scilex Holding Company
Published: 2023-10-03 (Crawled : 13:00) - globenewswire.com
SCLX | $0.984 3.43% 3.31% 550K
|
|
| O: -0.75%
H: 0.42%
C: -4.55%
SRNE | $0.015 -8.85% 140K
|
Health Technology
|
| O: 4.21%
H: 0.0%
C: -6.06%
company
Scilex Holding Company Announces the Consummation of the Previously Announced Purchase of all of the Scilex Common Shares, Preferred Shares and Warrants Owned by Sorrento Therapeutics, Inc.
Published: 2023-09-21 (Crawled : 20:00) - globenewswire.com
SCLX | $0.984 3.43% 3.31% 550K
|
|
| O: 0.0%
H: 2.86%
C: -9.71%
SRNE | $0.015 -8.85% 140K
|
Health Technology
|
| O: -1.64%
H: 12.33%
C: -0.92%
ORMP A | $2.39 2.58% 2.51% 31K
|
Health Technology
|
| O: -3.04%
H: 3.53%
C: 1.96%
company
Scilex Holding Company Announces the Completion of its SP-103 (lidocaine topical system) 5.4%, Triple Strength Formulation of ZTlido®, Phase 2 trial which achieved its objectives to Evaluate the Safety and Efficacy of SP-103 in Subjects with Moderate to Severe Acute Lower Back Pain (LBP)
Published: 2023-09-14 (Crawled : 13:00) - globenewswire.com
SCLX | $0.984 3.43% 3.31% 550K
|
|
| O: 0.9%
H: 2.22%
C: -0.44%
SRNE | $0.015 -8.85% 140K
|
Health Technology
|
| O: -0.43%
H: 4.35%
C: 0.0%
sp-103 ztlido back trial
Scilex Holding Company Enters into Non-Binding Term Sheets for the Purchase of all of the Scilex Common Shares, Preferred Shares, and Warrants Currently Owned by Sorrento Therapeutics, Inc. and is Declared the New Successful Bidder
Published: 2023-09-13 (Crawled : 13:00) - globenewswire.com
SCLX | $0.984 3.43% 3.31% 550K
|
|
| O: 1.23%
H: 0.0%
C: -9.72%
SRNE | $0.015 -8.85% 140K
|
Health Technology
|
| O: -6.99%
H: 39.83%
C: 33.53%
ORMP A | $2.39 2.58% 2.51% 31K
|
Health Technology
|
| O: 0.65%
H: 0.0%
C: -6.17%
Scilex Holding Company Presented Oral and Poster Presentations on ZTlido (lidocaine topical system) at the 2023 Annual PAINWeek Conference Held in Las Vegas, NV
Published: 2023-09-12 (Crawled : 13:30) - globenewswire.com
SCLX | $0.984 3.43% 3.31% 550K
|
|
| O: 2.49%
H: 2.83%
C: -1.21%
SRNE | $0.015 -8.85% 140K
|
Health Technology
|
| O: -3.62%
H: 7.95%
C: -8.1%
conference ztlido
Sorrento Announces Phase 3 Trial Met Primary Endpoint and Key Secondary Endpoint in Mild or Moderate COVID-19 Adult Patients Treated with Ovydso (Olgotrelvir), an Oral Mpro Inhibitor as a Standalone Treatment for COVID-19
Published: 2023-09-12 (Crawled : 13:30) - globenewswire.com
SRNE | $0.015 -8.85% 140K
|
Health Technology
|
| O: -3.62%
H: 7.95%
C: -8.1%
covid-19 treatment trial
Scilex Holding Company Presented Oral and Poster Presentations on Elyxyb at the 2023 Annual Brain Week Conference Held in Las Vegas, NV
Published: 2023-09-12 (Crawled : 13:30) - globenewswire.com
SCLX | $0.984 3.43% 3.31% 550K
|
|
| O: 2.49%
H: 2.83%
C: -1.21%
SRNE | $0.015 -8.85% 140K
|
Health Technology
|
| O: -3.62%
H: 7.95%
C: -8.1%
conference week
Scilex Holding Company Generates Record Monthly Revenue In August 2023 And Provides Certain Preliminary Unaudited Financial Results For Gross And Net Sales For The One Month Ended August 2023, And Year-To-Date As Of August 31 2023, Based On Currently Available Information
Published: 2023-09-11 (Crawled : 13:00) - globenewswire.com
SCLX | $0.984 3.43% 3.31% 550K
|
|
| O: 2.36%
H: 2.69%
C: -7.31%
SRNE | $0.015 -8.85% 140K
|
Health Technology
|
| O: 0.64%
H: 0.63%
C: -11.21%
sales one financial results
Sorrento Therapeutics Announces Positive Phase 2a Clinical Trial Results for Resiniferatoxin (RTX) for the Treatment of Knee Pain in Moderate to Severe Osteoarthritis of the Knee (OAK) Patients
Published: 2023-09-07 (Crawled : 13:00) - globenewswire.com
SRNE | $0.015 -8.85% 140K
|
Health Technology
|
| O: 0.52%
H: 42.58%
C: 36.03%
osteoarthritis positive treatment trial therapeutics results
Processa Pharmaceuticals Appoints Life Sciences Industry Veteran George Ng as Chief Executive Officer
Published: 2023-08-08 (Crawled : 12:20) - globenewswire.com
SRNE | $0.015 -8.85% 140K
|
Health Technology
|
| O: 1.34%
H: 0.8%
C: -5.31%
PCSA | $1.53 -2.27% 25K
|
Producer Manufacturing
|
| O: 2.44%
H: 0.02%
C: -7.14%
life pharmaceuticals sciences
Sorrento Issues a “FAQ” in Response to Large Number Of Urgent Requests from Scilex Dividend Short Holders and/or Record Holders
Published: 2023-07-27 (Crawled : 13:00) - globenewswire.com
SCLX | $0.984 3.43% 3.31% 550K
|
|
| O: 0.79%
H: 3.32%
C: 2.54%
SRNE | $0.015 -8.85% 140K
|
Health Technology
|
| O: -1.27%
H: 8.44%
C: 8.04%
response
Gainers vs Losers
| 78% | 22% |
Top 10 Gainers
MTTR | News 4 | $4.6 164.37% 62.17% 28M
|
AGBA | $2.94 135.2% 57.48% 66M
|
Finance
EDBL | News | $6.46 71.81% 41.8% 2M
|
MTC | $2.25 44.23% 30.67% 6M
|
Technology Services
OPRT | News | $3.175 41.11% 29.13% 12M
|
Finance
SHIM | $3.05 35.56% 26.23% 1.1M
|
HKIT | $1.345 31.86% 24.16% 390K
|
Technology Services
ABVC | $1.36 30.77% 23.53% 7.4M
|
Wholesale Trade
OST | $0.512 28.0% 21.88% 290K
|
POET | $1.59 27.2% 21.38% 4.2M
|
Manufacturing
Your saved searches
Save your searches and get alerts when important news are released.